Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
DVAX's Cash to Debt is ranked higher than
81% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. DVAX: No Debt )
DVAX' s 10-Year Cash to Debt Range
Min: 2.34   Max: No Debt
Current: No Debt

Equity to Asset 0.83
DVAX's Equity to Asset is ranked higher than
85% of the 937 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. DVAX: 0.83 )
DVAX' s 10-Year Equity to Asset Range
Min: -2.28   Max: 0.93
Current: 0.83

-2.28
0.93
Interest Coverage No Debt
DVAX's Interest Coverage is ranked higher than
59% of the 582 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. DVAX: No Debt )
DVAX' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 4
Z-Score: 3.07
M-Score: -3.43
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -705.83
DVAX's Operating margin (%) is ranked higher than
59% of the 1026 Companies
in the Global Biotechnology industry.

( Industry Median: -75.73 vs. DVAX: -705.83 )
DVAX' s 10-Year Operating margin (%) Range
Min: -2150.61   Max: -37.49
Current: -705.83

-2150.61
-37.49
Net-margin (%) -702.40
DVAX's Net-margin (%) is ranked higher than
59% of the 1026 Companies
in the Global Biotechnology industry.

( Industry Median: -78.15 vs. DVAX: -702.40 )
DVAX' s 10-Year Net-margin (%) Range
Min: -2100.73   Max: -56.15
Current: -702.4

-2100.73
-56.15
ROE (%) -57.81
DVAX's ROE (%) is ranked higher than
66% of the 1147 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. DVAX: -57.81 )
DVAX' s 10-Year ROE (%) Range
Min: -307.22   Max: -30.62
Current: -57.81

-307.22
-30.62
ROA (%) -50.29
DVAX's ROA (%) is ranked higher than
64% of the 1253 Companies
in the Global Biotechnology industry.

( Industry Median: -27.49 vs. DVAX: -50.29 )
DVAX' s 10-Year ROA (%) Range
Min: -85.08   Max: -19.74
Current: -50.29

-85.08
-19.74
ROC (Joel Greenblatt) (%) -959.75
DVAX's ROC (Joel Greenblatt) (%) is ranked higher than
69% of the 1227 Companies
in the Global Biotechnology industry.

( Industry Median: -437.61 vs. DVAX: -959.75 )
DVAX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2870.62   Max: -172.67
Current: -959.75

-2870.62
-172.67
Revenue Growth (3Y)(%) -41.90
DVAX's Revenue Growth (3Y)(%) is ranked higher than
62% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. DVAX: -41.90 )
DVAX' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 88.1
Current: -41.9

0
88.1
EBITDA Growth (3Y)(%) -19.80
DVAX's EBITDA Growth (3Y)(%) is ranked higher than
65% of the 714 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. DVAX: -19.80 )
DVAX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -63.4   Max: 39.1
Current: -19.8

-63.4
39.1
EPS Growth (3Y)(%) -18.00
DVAX's EPS Growth (3Y)(%) is ranked higher than
69% of the 729 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. DVAX: -18.00 )
DVAX' s 10-Year EPS Growth (3Y)(%) Range
Min: -60.6   Max: 26
Current: -18

-60.6
26
» DVAX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

DVAX Guru Trades in Q4 2013

Jim Simons 1,562,513 sh (+339.7%)
Steven Cohen 7,577,533 sh (+278.88%)
John Burbank Sold Out
» More
Q1 2014

DVAX Guru Trades in Q1 2014

Jim Simons Sold Out
Steven Cohen Sold Out
» More
Q2 2014

DVAX Guru Trades in Q2 2014

Jim Simons 1,139,293 sh (New)
» More
Q3 2014

DVAX Guru Trades in Q3 2014

Jim Simons 131,694 sh (-88.44%)
» More
» Details

Insider Trades

Latest Guru Trades with DVAX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Burbank 2013-12-31 Sold Out 0.05%$11.1 - $20 $ 15.345%0
John Burbank 2013-09-30 New Buy$10.6 - $14.3 $ 15.3422%6349.2
George Soros 2012-06-30 Sold Out 0.03%$35.5 - $52.1 $ 15.34-64%0
George Soros 2012-03-31 Reduce -62.5%0.09%$32.8 - $49.4 $ 15.34-60%37500
George Soros 2011-12-31 New Buy0.14%$18.2 - $33.3 $ 15.34-45%100000
George Soros 2011-09-30 Sold Out 0.0026%$18.4 - $31.6 $ 15.34-37%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.30
DVAX's P/B is ranked higher than
82% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 6.25 vs. DVAX: 3.30 )
DVAX' s 10-Year P/B Range
Min: 0.65   Max: 14.93
Current: 3.3

0.65
14.93
P/S 33.30
DVAX's P/S is ranked higher than
73% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 28.14 vs. DVAX: 33.30 )
DVAX' s 10-Year P/S Range
Min: 0.18   Max: 78.37
Current: 33.3

0.18
78.37
EV-to-EBIT -3.22
DVAX's EV-to-EBIT is ranked higher than
85% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. DVAX: -3.22 )
DVAX' s 10-Year EV-to-EBIT Range
Min: -26.2   Max: 6.3
Current: -3.22

-26.2
6.3
Current Ratio 5.91
DVAX's Current Ratio is ranked higher than
78% of the 1242 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. DVAX: 5.91 )
DVAX' s 10-Year Current Ratio Range
Min: 1.87   Max: 13.98
Current: 5.91

1.87
13.98
Quick Ratio 5.91
DVAX's Quick Ratio is ranked higher than
79% of the 1242 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. DVAX: 5.91 )
DVAX' s 10-Year Quick Ratio Range
Min: 1.87   Max: 13.98
Current: 5.91

1.87
13.98

Valuation & Return

vs
industry
vs
history
Price/Net Cash 3.76
DVAX's Price/Net Cash is ranked higher than
92% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 53.79 vs. DVAX: 3.76 )
DVAX' s 10-Year Price/Net Cash Range
Min: 1.81   Max: 26.38
Current: 3.76

1.81
26.38
Price/Net Current Asset Value 3.74
DVAX's Price/Net Current Asset Value is ranked higher than
92% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 31.40 vs. DVAX: 3.74 )
DVAX' s 10-Year Price/Net Current Asset Value Range
Min: 1.79   Max: 50.59
Current: 3.74

1.79
50.59
Price/Tangible Book 3.32
DVAX's Price/Tangible Book is ranked higher than
87% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 9.45 vs. DVAX: 3.32 )
DVAX' s 10-Year Price/Tangible Book Range
Min: 1.69   Max: 27.84
Current: 3.32

1.69
27.84
Price/Median PS Value 2.37
DVAX's Price/Median PS Value is ranked higher than
73% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. DVAX: 2.37 )
DVAX' s 10-Year Price/Median PS Value Range
Min: 0.04   Max: 5.1
Current: 2.37

0.04
5.1
Earnings Yield (Greenblatt) -31.10
DVAX's Earnings Yield (Greenblatt) is ranked higher than
55% of the 1221 Companies
in the Global Biotechnology industry.

( Industry Median: -6.20 vs. DVAX: -31.10 )
DVAX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 16   Max: 3563.3
Current: -31.1

16
3563.3

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:DYF1.Germany,
Dynavax Technologies Corp was incorporated in California in August 1996 under the name Double Helix Corporation, and it changed its name to Dynavax Technologies Corporation in September 1996. The Company reincorporated in Delaware in 2000. The Company is a clinical-stage biopharmaceutical company. It discovers and develops novel products to prevent and treat infectious and inflammatory diseases. The Company's product candidate is HEPLISAVTM, a Phase 3 investigational adult hepatitis B vaccine. Its pipeline of product candidates includes: HEPLISAV, its autoimmune program partnered with GlaxoSmithKline, and its therapy for asthma partnered with AstraZeneca AB. Its product candidates are based on the use of immunostimulatory and immunoregulatory sequences. HEPLISAV is an investigational adult hepatitis B vaccine. In Phase 3 trials, HEPLISAV demonstrated higher and earlier protection with fewer doses than currently licensed vaccines. The Company has worldwide commercial rights to HEPLISAV. HEPLISAV combines its first generation 1018 ISS with hepatitis B surface antigen manufactured in its facility in Düsseldorf, Germany. The Company competes with pharmaceutical companies, biotechnology companies, academic institutions and research organizations, in developing therapies to prevent or treat infectious diseases and inflammatory and autoimmune diseases. Any product candidate it develops is subject to extensive regulation by federal, state and local governmental authorities in the United States, including the FDA and foreign regulatory agencies.
» More Articles for DVAX

Headlines

Articles On GuruFocus.com
Dynavax Announces Webcast of R&D Day Dec 09 2014 
Dynavax and AstraZeneca to Advance TLR9 Agonist for Treatment of Asthma Into Phase 2a Clinical Study Dec 08 2014 
Dynavax Regains Full Rights to Investigational TLR 7/9 Inhibitor DV1179 Following Expiration of Coll Nov 28 2014 
Dynavax Announces Independent DSMB Recommendation to Continue Phase 3 Study of HEPLISAV-B(TM) Nov 10 2014 
Dynavax Reports Third Quarter 2014 Financial Results Nov 05 2014 
Dynavax Announces Resignation of Dino Dina From Board of Directors Oct 15 2014 
Dynavax Initiates Phase 1/2 Study of TLR-9 Agonist Immunotherapy in B-Cell Lymphoma Oct 15 2014 
Two Promising Health Care Stocks with Market Capitalizations Under $500 Million Jun 11 2014 
Top Three Largest Insider Buys of the Past Week Nov 05 2013 
About to submit BLA Mar 11 2012 

More From Other Websites
Dynavax & AstraZeneca Alter Agreement for Asthma Product Dec 09 2014
Dynavax Announces Webcast of R&D Day Dec 09 2014
Dynavax Announces Webcast of R&D Day Dec 09 2014
DYNAVAX TECHNOLOGIES CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... Dec 08 2014
Dynavax and AstraZeneca to Advance TLR9 Agonist for Treatment of Asthma Into Phase 2a Clinical Study Dec 08 2014
Dynavax and AstraZeneca to Advance TLR9 Agonist for Treatment of Asthma Into Phase 2a Clinical Study Dec 08 2014
Dynavax Regains TLR 7/9 Inhibitor DV1179 Rights from Glaxo Dec 01 2014
DYNAVAX TECHNOLOGIES CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Nov 28 2014
Dynavax Regains Full Rights to Investigational TLR 7/9 Inhibitor DV1179 Following Expiration of... Nov 28 2014
Dynavax Regains Full Rights to Investigational TLR 7/9 Inhibitor DV1179 Following Expiration of... Nov 28 2014
Lightning Round: You're playing with fire Nov 21 2014
DYNAVAX TECHNOLOGIES CORP Financials Nov 14 2014
Dynavax's Heplisav Phase III Trial Recommended to Continue Nov 11 2014
DYNAVAX TECHNOLOGIES CORP Files SEC form 8-K, Entry into a Material Definitive Agreement,... Nov 10 2014
Dynavax Announces Independent DSMB Recommendation to Continue Phase 3 Study of HEPLISAV-B(TM) Nov 10 2014
Dynavax Announces Independent DSMB Recommendation to Continue Phase 3 Study of HEPLISAV-B(TM) Nov 10 2014
10-Q for Dynavax Technologies Corp. Nov 07 2014
Dynavax Announces One-for-Ten Reverse Stock Split Nov 07 2014
Dynavax Announces One-for-Ten Reverse Stock Split Nov 07 2014
DYNAVAX TECHNOLOGIES CORP Files SEC form 8-K, Results of Operations and Financial Condition,... Nov 05 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK